You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
|
|---|---|
| Published in |
Bone Marrow Transplantation, September 2016
|
| DOI | 10.1038/bmt.2016.213 |
| Pubmed ID | |
| Authors |
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, R Bouadballah, J Radford, M Bargetzi, V Ribrag, U Dührsen, D Ma, J Briere, C Thieblemont, E Bachy, C H Moskowitz, B Glass, C Gisselbrecht |
| Abstract |
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed <6 months (5.7 months) compared with those relapsing ⩾12 months after ASCT (12.6 months, P=0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P<0.0001), 10.0 (P=0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and >2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting <6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.Bone Marrow Transplantation advance online publication, 19 September 2016; doi:10.1038/bmt.2016.213. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 21% |
| Canada | 2 | 11% |
| Argentina | 1 | 5% |
| United Kingdom | 1 | 5% |
| Spain | 1 | 5% |
| Australia | 1 | 5% |
| Egypt | 1 | 5% |
| Unknown | 8 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 53% |
| Scientists | 5 | 26% |
| Practitioners (doctors, other healthcare professionals) | 3 | 16% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 125 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 25 | 20% |
| Other | 20 | 16% |
| Student > Master | 7 | 6% |
| Student > Doctoral Student | 6 | 5% |
| Student > Ph. D. Student | 6 | 5% |
| Other | 19 | 15% |
| Unknown | 43 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 38% |
| Biochemistry, Genetics and Molecular Biology | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Economics, Econometrics and Finance | 6 | 5% |
| Agricultural and Biological Sciences | 3 | 2% |
| Other | 10 | 8% |
| Unknown | 46 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2023.
All research outputs
#1,807,487
of 25,378,284 outputs
Outputs from Bone Marrow Transplantation
#148
of 4,081 outputs
Outputs of similar age
#31,049
of 328,381 outputs
Outputs of similar age from Bone Marrow Transplantation
#3
of 51 outputs
Altmetric has tracked 25,378,284 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,081 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,381 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.